智利引入ACWY群脑膜炎球菌结合疫苗七年后的侵袭性脑膜炎球菌病
智利在2012年起为儿童接种四价脑膜炎球菌结合疫苗(MCV-ACWY)并于2014年纳入国家免疫规划后,描述2009至2019年侵袭性脑膜炎球菌病(IMD)病例及趋势。结果显示2015至2019年总体IMD和W群病例下降,B群、C群和Y群稳定,W群在各年龄组(包括未免疫婴儿和60岁以上人群)下降,但2019年病死率仍高,需进一步分析和更长观察期以得出更稳健结论。
要点
- 2015至2019年总体IMD和W群病例下降,B群、C群和Y群稳定。
- W群发病率在各年龄组下降,包括未免疫婴儿和60岁以上人群。
- 2019年总体病死率为19%,W群为24.5%,仍较高。
核心结论
- 自2015年MCV-ACWY引入后,总体IMD、W群病例和发病率下降,而B群、C群和Y群保持稳定。
- W群发病率在所有年龄组下降,包括未免疫婴儿和60岁以上人群。
- 需要进一步分析和更长观察期才能对此流行病学趋势得出更稳健结论。
- 截至2019年,病死率仍高。
研究设计与样本
- 描述性研究,分析智利2009至2019年IMD病例、每10万居民累积发病率、病死率(CFR)和疫苗接种率。
- 数据来源于公共卫生研究所和国家免疫规划(NIP)。
主要发现
- 总体IMD病例在2009至2014年增加,随后在2015至2019年下降,主要集中在婴儿、5岁以下儿童和60岁及以上人群。
- B群(MenB)和W群(MenW)交替占优势。
- 总体发病率中位数从2009年0.6/10万升至2014年0.8/10万,后降至2019年0.4/10万。
- B群、C群和Y群发病率中位数分别为0.25/10万、<0.01/10万和<0.01/10万。
- W群发病率中位数从2009年0.01/10万升至2014年0.56/10万,后持续下降至2019年0.12/10万。
局限性
- 需要进一步分析和更长观察期才能对此流行病学趋势得出更稳健结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A serogroup W (MenW) outbreak in Chile prompted a meningococcal vaccination campaign using tetravalent meningococcal-conjugate vaccines (MCV-ACWY) in children since 2012, followed by its introduction into the National Immunization Program (NIP) in toddlers from 2014. Direct protection was observed, but no indirect effects in other age-groups were evidenced. The aim of this study was to describe invasive meningococcal disease (IMD) cases in Chile between 2009 and 2019, and its trend after the introduction of MCV-ACWYs. METHODS: IMD cases, cumulative incidence per 100,000 inhabitants, CFR, and vaccination uptake were described. Data were obtained from the Public Health Institute and NIP. RESULTS: Overall-IMD cases increased in 2009-2014 period, followed by a decline in 2015-2019, focused in infants, children <5 years and people ≥60 years. Serogroup B (MenB) and MenW alternate its predominance. Median overall incidence was 0.6/100,000, increasing from 0.6/100,000 in 2009 to 0.8/100,000 in 2014, later decreasing to 0.4/100,000 in 2019. Median incidences for MenB, serogroup C (MenC) and Y (MenY) were 0.25/100,000, <0.01/100,000 and <0.01/100,000, respectively. Median MenW incidence was 0.53/100,000, increasing from 0.01/100,000 in 2009 to 0.56/100,000 in 2014, followed by a constant decline to 0.12 in 2019. Infants, children <5 years and adults ≥60 years were affected the most, with median incidences of 9.7, 0.9 and 0.93, decreasing to 1.3, 0.1 and 0.1/100,000 in 2019, respectively. Median overall-CFR was 19%, 7.5% for MenB and 24.5% for MenW. Median MCV-ACWY uptake was 93% CONCLUSION: Overall-IMD, MenW cases and incidence declined since 2015 after the MCV-ACWY introduction, while MenB, MenC and MenY have been stable. MenW incidence declined in all age groups, including non-immunized infants and people >60 years. Further analysis and a longer period of observation are needed to have a more robust conclusion about this epidemiological trend. By 2019, CFR remains high.
引用
- Villena R, Valenzuela MT, Bastías M, et al. Invasive meningococcal disease in Chile seven years after ACWY conjugate vaccine introduction. Vaccine. 2022. PMID: 34996641. doi:10.1016/j.vaccine.2021.11.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。